Modality
mAb
MOA
GLP-1ag
Target
SMN2
Pathway
Notch
MS
Development Pipeline
Preclinical
Oct 2017
→ Jun 2030
PreclinicalCurrent
NCT08710084
2,668 pts·MS
2017-10→2030-06·Completed
NCT04165297
2,920 pts·MS
2020-11→2030-05·Completed
5,588 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-05-144.1y awayInterim· MS
2030-06-284.2y awayInterim· MS
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2030-05-14 · 4.1y away
MS
Interim
2030-06-28 · 4.2y away
MS
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08710084 | Preclinical | MS | Completed | 2668 | CfB |
| NCT04165297 | Preclinical | MS | Completed | 2920 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR |